| A review of the efficacy and safety of oral antidiabetic drugs. | |
| | |
MedLine Citation:
|
PMID: 23241069 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Introduction: Additional oral antidiabetic agents to metformin, sulfonylureas (SU) and thiazolidinediones (TZD) are approved for the treatment of type 2 diabetes. Areas covered: The efficacy and safety of metformin, SUs, TZDs, dipeptidyl peptidase-IV (DPP-4) inhibitors, meglitinide analogs, α-glucosidase inhibitors (AGIs), bile-acid sequestrants (BAS) and bromocriptine will be reviewed. Expert opinion: Several new oral agents have been approved for type 2 diabetes management in recent years. It is important to understand the efficacy and safety of these medications in addition to the older agents to best maximize oral drug therapy for diabetes. Of the recently introduced oral hypoglycemic/antihyperglycemic agents, the DPP-4 inhibitors are moderately efficacious compared with mainstay treatment with metformin with a low side-effect profile and have good efficacy in combination with other oral agents and insulin. They are a recommended alternative when metformin use is limited by gastrointestinal (GI) side effects or when SU treatment results in significant hypoglycemia or weight gain. Meglitinide analogs are limited by their frequent dosing, expense and hypoglycemia (repaglinide > nateglinide), while AGIs are also limited by their dosing schedule and GI side-effect profile. BAS and bromocriptine have the lowest efficacy with regard to HbA(1c) reduction, also are plagued by GI adverse reactions, but have a low risk of hypoglycemia. |
| | |
Authors:
|
Stephanie Aleskow Stein; Elizabeth Mary Lamos; Stephen N Davis |
Related Documents
:
|
23290729 - Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. 16928589 - Diabetic screening in western australia: a photographer's perspective. 23223219 - Intrarenal arterial resistance is associated with microvascular complications in chines... 23021699 - Insulin pump dosing across gestation in women with well-controlled type 1 diabetes mell... 23209929 - Insulin therapy and cancer in type 2 diabetes. 19628949 - Selective versus universal screening for gestational diabetes mellitus: an evaluation o... 3542619 - Cholesterol and bile acid metabolism in middle-aged diabetics. 19344959 - The value of glycosylated hemoglobin (hba1c) as a predictive risk factor in the diagnos... 6581479 - Hla antigens and necrobiosis lipoidica diabeticorum--a comparison between insulin-depen... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-12-14 |
Journal Detail:
|
Title: Expert opinion on drug safety Volume: - ISSN: 1744-764X ISO Abbreviation: Expert Opin Drug Saf Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-12-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101163027 Medline TA: Expert Opin Drug Saf Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
University of Maryland Medical Center, Endocrinology, Diabetes and Metabolism , 22 South Greene St. N3W157, Baltimore, MD 21201 , USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sulfocoumarins (1,2-benzoxathiine 2,2-dioxides): a class of potent and isoform-selective inhibitors ...
Next Document: Excision of the Deep Branch of the Lateral Palmar Nerve of Horses to Resolve Lameness Caused by Prox...